TY - JOUR
T1 - SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients
T2 - a randomized clinical trial (VATICO Trial)
AU - the ACTIV-3/VATICO study group and the STRIVE Network
AU - Clinical Sites by Country
AU - INSIGHT Community Advisory Board
AU - Statistical and Data Management Center, Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, United States
AU - Foundation for the National Institutes of Health, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) and Operation Warp Speed, North Bethesda, Maryland, United States
AU - Frederick National Laboratory for Cancer Research/Leidos Biomedical Research, Inc., Frederick, Maryland, United States
AU - US. National Institute of Allergy and Infectious Diseases (including Department of Clinical Research International Coordinating Center), Bethesda, Maryland, United States
AU - Washington ICC, Veterans Affairs Medical Center, Washington, DC, United States
AU - Veterans Affairs ICC, US Department of Veterans Affairs, Washington DC, United States
AU - Sydney ICC, The Kirby Institute, University of New South Wales, Sydney, Australia
AU - Nashville ICC, Vanderbilt University Medical Center, Nashville, Tennessee, United States
AU - London ICC, MRC Clinical Trials Unit at UCL, London, United Kingdom
AU - Copenhagen ICC, CHIP (Centre of Excellence for Health, Immunity and Infections), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
AU - Cardiothoracic Surgical Trials Network (CTSN) ICC, Icahn School of Medicine at Mount Sinai, New York, New York, United States
AU - International Coordinating Centers (ICCs)
AU - Sábato, Sofía
AU - Benet, Susana
AU - Rogers, Angela J.
AU - Murray, Thomas A.
AU - Skeans, Melissa
AU - Mothe, Beatriz
AU - Paredes, Roger
AU - Mourad, Ahmad
AU - Kiweewa, Francis
AU - Kamel, Dena
AU - Jain, Mamta K.
AU - Lutaakome, Joseph
AU - Nalubega, Mary Grace
AU - Sebudde, Nicholus
AU - Mylonakis, Eleftherios
AU - Braun, Dominique L.
AU - Hatlen, Timothy
AU - Kimuli, Ivan
AU - Kitko, Cissy
AU - Mugerwa, Henry
AU - Kitonsa, Jonathan
AU - Kim, Kami
AU - Tien, Phyllis C.
AU - Highbarger, Jeroen
AU - McCormack, Ashley L.
AU - Sanchez, Adriana
AU - Murray, Daniel D.
AU - Babiker, Abdel G.
AU - Davey, Victoria J.
AU - Files, D. Clark
AU - Gelijns, Annetine C.
AU - Higgs, Elizabeth S.
AU - Kan, Virginia L.
AU - Matthews, Gail V.
AU - Pett, Sarah L.
AU - Lane, H. Clifford
AU - Reilly, Cavan
AU - Goodman, Anna L.
AU - Lundgren, Jens D.
AU - Moltó, José
AU - Yeo, He Ping
AU - Diong, Shaiu Hui
AU - Ong, Sean W.X.
AU - Chia, Po Ying
AU - Young, Barnaby E.
AU - Uche, Blessing
AU - Idoko, Godwin
AU - Habib, Zaiyad
AU - Moskowitz, Alan
AU - Gelijns, Annetine
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - The impact on immunogenicity and efficacy of SARS-CoV-2 vaccination in people with prior COVID-19 could differ depending on timing of vaccination and number of doses. The VATICO study randomized 66 hospitalized recovered COVID-19 individuals to receive either immediate or deferred vaccination, with one or two doses of mRNA SARS-CoV-2 vaccines. We measured binding and neutralizing antibodies against SARS-CoV-2 at enrollment and longitudinally. Median (IQR) time from SARS-CoV-2 infection to first vaccination was 68 (53–75) days in the immediate group, and 151 (137–173) days in the deferred group. At week 48, timing or number of vaccine doses did not influence the change in antibody levels relative to baseline. Adherence to the assigned vaccine regimen was lower in the deferred group, particularly in participants receiving two doses. Although the study ultimately lacked adequate power to draw firm conclusions, these results suggest possible benefits of prompt vaccination after recovery from COVID-19.
AB - The impact on immunogenicity and efficacy of SARS-CoV-2 vaccination in people with prior COVID-19 could differ depending on timing of vaccination and number of doses. The VATICO study randomized 66 hospitalized recovered COVID-19 individuals to receive either immediate or deferred vaccination, with one or two doses of mRNA SARS-CoV-2 vaccines. We measured binding and neutralizing antibodies against SARS-CoV-2 at enrollment and longitudinally. Median (IQR) time from SARS-CoV-2 infection to first vaccination was 68 (53–75) days in the immediate group, and 151 (137–173) days in the deferred group. At week 48, timing or number of vaccine doses did not influence the change in antibody levels relative to baseline. Adherence to the assigned vaccine regimen was lower in the deferred group, particularly in participants receiving two doses. Although the study ultimately lacked adequate power to draw firm conclusions, these results suggest possible benefits of prompt vaccination after recovery from COVID-19.
UR - https://www.scopus.com/pages/publications/105001881926
U2 - 10.1038/s41598-025-92742-x
DO - 10.1038/s41598-025-92742-x
M3 - Article
C2 - 40118946
AN - SCOPUS:105001881926
SN - 2045-2322
VL - 15
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 9882
ER -